FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 665 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic Pontine Glioma Linked to TP53 Alterations A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab MOST POPULAR Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents December 15, 2022 Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with... November 20, 2020 GreaterGood’s Mask Donations Are Helping LA Family Housing Keep Homeless People... October 26, 2020 EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... April 3, 2025 Load more HOT NEWS How To Respond When Your Parents Are Critical Of Your Parenting... Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant... Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced... FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular...
